Increased Protein Expression Vector for Vaccine Applications


An expression vector with a unique promoter that results in higher level of protein expression than vectors currently in use is available for licensing from the NIH. The elevated levels of expression are achieved through use of a specific promoter, known as CMV/R, in which the Human T-Lymphotrophic Virus (HTLV-1) Long Terminal Repeat (LTR) R-U5 region is substituted for a portion of the intron downstream of the CMV immediate early region 1 enhancer (Barouch et al., 2005). Sequences of 95% or better homology to CMV/R can be used as well. CMV/R vectors are currently being used in a number of clinical trials, including vaccines against West Nile Virus, Ebola virus, and HIV and achieving promising results. The related HIV vaccine technology is available for licensing, as is the Ebola DNA vaccine technology (non-exclusive licensing only). The CMV/R vector can be used for any DNA vaccine or for the production of recombinant proteins in high yields.

Potential Commercial Applications: Competitive Advantages:
  • Vector for DNA vaccines
  • High yield expression of recombinant proteins
 


Inventors:

Gary Nabel (NIAID)  ➽ more inventions...

Zhi-yong Yang (NIAID)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 7,635,688 issued 2009-12-22
U.S. Pat: 8,106,026 issued 2012-01-31
U.S. Pat: 8,106,027 issued 2012-01-31
U.S. Pat: 8,124,592 issued 2012-02-28
PCT Application No. 12/612,621
US Application No. 12/612,625
US Application No. 13/010,141

Licensing Contact:
Carol Salata, Ph.D.
Email: csalata@mail.nih.gov
Phone: 240-627-3727

OTT Reference No: E-241-2001-0
Updated: Jun 1, 2007